Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06584435
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-02
Brief Title:
A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TUOAD-RCC
Brief Summary:
This is a phase II study to investigate the effect of treprolizumab on tumor control and survival in high-risk renal cancer after radical nephrectomy Patients will be treated with treprolizumab which will be administered every 3 weeks until tumor recurrence or intolerable toxicities
Detailed Description:
This is a phase II study to investigate the effect of treprolizumab on tumor control and survival in high-risk renal cancer after radical nephrectomy Patients will be treated with treprolizumab which will be administered every 3 weeks until tumor recurrence or intolerable toxicities The primary outcome measure was PFS and OS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None